TD Asset Management Inc Reduces Position in Generation Bio Co. $GBIO

TD Asset Management Inc trimmed its holdings in Generation Bio Co. (NASDAQ:GBIO) by 92.2% in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 26,708 shares of the company’s stock after selling 313,978 shares during the quarter. TD Asset Management Inc owned about 0.40% of Generation Bio worth $163,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Acadian Asset Management LLC boosted its holdings in shares of Generation Bio by 54.3% during the 1st quarter. Acadian Asset Management LLC now owns 1,159,135 shares of the company’s stock valued at $468,000 after acquiring an additional 407,843 shares during the last quarter. Militia Capital Partners LP bought a new stake in shares of Generation Bio in the second quarter worth approximately $174,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Generation Bio in the second quarter worth approximately $47,000. Marshall Wace LLP purchased a new position in shares of Generation Bio during the second quarter valued at approximately $37,000. Finally, AQR Capital Management LLC purchased a new position in shares of Generation Bio during the first quarter valued at approximately $36,000. Hedge funds and other institutional investors own 95.22% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Wall Street Zen upgraded shares of Generation Bio to a “sell” rating in a report on Saturday, February 14th. Wedbush set a $5.50 target price on shares of Generation Bio and gave the company an “outperform” rating in a research note on Tuesday, December 16th. Zacks Research raised Generation Bio to a “hold” rating in a report on Monday, January 26th. Citigroup restated a “market perform” rating on shares of Generation Bio in a research note on Wednesday, December 17th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Generation Bio in a report on Thursday, January 22nd. Three analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Generation Bio currently has a consensus rating of “Hold” and a consensus price target of $8.88.

Generation Bio Price Performance

Shares of Generation Bio stock opened at $5.34 on Friday. Generation Bio Co. has a 1-year low of $3.00 and a 1-year high of $8.20. The company’s fifty day simple moving average is $5.49 and its 200-day simple moving average is $5.66. The stock has a market capitalization of $35.99 million, a PE ratio of -0.57 and a beta of 2.05.

About Generation Bio

Generation Bio, Inc (NASDAQ: GBIO) is a clinical-stage genetic medicine company dedicated to developing ultra-long-term non-viral gene therapies for serious, chronic diseases. Headquartered in Cambridge, Massachusetts, Generation Bio focuses on harnessing its proprietary Gene Delivery System to deliver plasmid DNA payloads via lipid nanoparticles, enabling durable expression of therapeutic proteins in target tissues without the use of viral vectors.

The company’s lead approach is centered on a modular platform designed to address monogenic disorders and other chronic conditions that require continuous protein replacement or modulation.